Key result
Percutaneous balloon pericardiotomy for malignant pericardial effusion resulted in a 95% live discharge rate and a 24.5% recurrence rate over a median follow-up of 6.3 months.
Why the study?
Use of percutaneous balloon pericardiotomy for malignant pericardial effusion is not standardized due to limited evidence, and performing a second procedure for recurrence remains controversial.
Does percutaneous balloon pericardiotomy provide safe and effective treatment in oncological patients with malignant pericardial effusion?
Observational (n=61)
No
Does percutaneous balloon pericardiotomy provide safe and effective treatment in oncological patients with malignant pericardial effusion?
Percutaneous balloon pericardiotomy is a safe and effective treatment for malignant pericardial effusion, and a second procedure is a viable option for recurrences.
PBP may offer safe palliation for MPE in oncology; leaves open need for randomized trials versus pericardiocentesis.
OBJECTIVES: The aim of this study was to analyze the efficacy and safety of percutaneous balloon pericardiotomy (PBP) in oncological patients who present with a malignant pericardial effusion (MPE). BACKGROUND: The use of PBP as a treatment for MPE is not standardized due to the limited evidence. Furthermore, the performance of a second PBP for a recurrence after a first procedure is controversial. METHODS: The BALTO Registry (BALloon pericardioTomy in Oncological patients) is a prospective, single-center, observational registry that includes consecutive PBP performed for MPE from October 2007 to February 2022. Clinical and procedural, characteristics, as well as clinical outcome were analyzed. RESULTS: Seventy-six PBP were performed in 61 patients (65% female). Mean age was of 66.4 ± 11.2 years. In 15 cases, a second PBP procedure was performed due to recurrence despite the first PBP. The procedure could be performed effectively in all cases with only two serious complications. Ninety-five percent of cases were discharged alive from the hospital. During a median follow-up of 6.3 months (interquartile range [IQR], 0.9-10.8), MPE recurred in 24.5% cases although no recurrences were reported after the second procedure. No evidence of malignant pleural effusion developed on follow-up. The median overall survival time was 5.8 months (IQR, 0.8-10.2) and the time to recurrence after the first PBP was 2.4 months (IQR, 0.7-4.5). CONCLUSIONS: PBP is a safe and effective treatment for MPE. It could be considered an acceptable therapy in most MPE, even in those who recur after a first procedure.
No takes yet. Share an insight, caveat, or question.
Santana et al. (2024) conducted an observational in Malignant pericardial effusion (n=61). Percutaneous balloon pericardiotomy was evaluated on Recurrence of malignant pericardial effusion. Percutaneous balloon pericardiotomy for malignant pericardial effusion resulted in a 95% live discharge rate and a 24.5% recurrence rate over a median follow-up of 6.3 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: